Detailed analysis of food-reinforced operant lever pressing distinguishes effects of a cannabinoid CB1 inverse agonist and dopamine D1 and D2 antagonists.
Overt similarities exist between the effects of systemic cannabinoid CB1 inverse agonists and dopamine (DA) antagonists on appetitive behavior. The present set of studies was undertaken to apply a fine-grained analysis of food-reinforced operant lever pressing in rats in order to compare the pattern of effects produced by administration of the CB1 inverse agonist AM 251 and those induced by the DA D1 antagonist SKF 83566, and the D2 antagonist raclopride. Three groups of rats were trained on a fixed-ratio 5 (FR5) schedule and administered these compounds over a range of doses expected to suppress responding. All three drugs produced a dose-related suppression of total lever pressing. In addition to main effects of dose, regression analyses were performed to determine which of several response timing- and rate-related variables correlated most strongly with overall responding in each group. It was found that total session time spent pausing from responding was significantly better at predicting responding in the AM 251 group, while both DA antagonists produced significantly stronger regression coefficients (versus AM 251) from fast responding measures. These results suggest that, while several similarities exist, CB1, D1, and D2 antagonists are not identical in their pattern of suppression of food-maintained lever pressing.
McLaughlin
P J
PJ
Department of Psychology, University of Connecticut, Storrs, CT 06269-1020, USA. pmclaughlin@edinboro.edu
Winston
K M
KM
Swezey
L A
LA
Vemuri
V K
VK
Makriyannis
A
A
Salamone
J D
JD
D000818:Animals; D002186:Cannabinoids / Q000494:pharmacology; D003216:Conditioning, Operant / Q000187:drug effects* / Q000502:physiology; D018492:Dopamine Antagonists / Q000494:pharmacology; D065127:Dopamine D2 Receptor Antagonists; D004305:Dose-Response Relationship, Drug; D054314:Drug Inverse Agonism; D005247:Feeding Behavior / Q000187:drug effects* / Q000502:physiology; D005502:Food; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D043884:Receptor, Cannabinoid, CB1 / Q000819:agonists* / Q000502:physiology; D017447:Receptors, Dopamine D1 / Q000037:antagonists & inhibitors* / Q000502:physiology; D017448:Receptors, Dopamine D2 / Q000502:physiology; D012055:Reinforcement Schedule
D002186:Cannabinoids; D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D043884:Receptor, Cannabinoid, CB1; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2
Behav Pharmacol. 2007 Nov;18(7):591-600
17912043
Brain Res. 1993 Nov 19;628(1-2):218-26
8313150
J Neurosci. 2008 Sep 3;28(36):9037-46
18768698
FEBS Lett. 1994 Aug 22;350(2-3):240-4
8070571
Neurosci Lett. 2007 Jun 4;419(3):231-5
17462824
Behav Pharmacol. 1994 Oct;5(6):615-622
11224241
Psychopharmacology (Berl). 2003 Feb;165(4):370-7
12447606
Eur J Pharmacol. 2003 Jun 27;471(3):185-93
12826237
Pharmacol Biochem Behav. 2000 Aug;66(4):803-9
10973519
J Exp Anal Behav. 1991 Sep;56(2):331-43
1955820
J Exp Anal Behav. 1974 Nov;22(3):553-60
16811820
Psychopharmacology (Berl). 2006 Jan;184(1):26-35
16328376
Life Sci. 1998;63(8):PL113-7
9718088
Physiol Behav. 2008 Jun 9;94(3):422-31
18394662
Psychopharmacology (Berl). 1997 Jul;132(1):104-6
9272766
Proc Natl Acad Sci U S A. 1990 Mar;87(5):1932-6
2308954
Neuroscience. 2002;109(3):451-60
11823058
Pharmacol Biochem Behav. 1993 Mar;44(3):605-10
8451265
Psychopharmacology (Berl). 1998 May;137(2):147-56
9630001
Neuroscience. 1990;39(1):17-24
2128534
Psychopharmacology (Berl). 2000 Sep;152(1):47-54
11041315
Brain Res. 1991 May 3;547(2):267-74
1909204
Psychopharmacology (Berl). 2009 Apr;203(3):475-87
19015837
Psychopharmacology (Berl). 1996 May;125(2):105-12
8783383
Br J Pharmacol. 2006 Jan;147(1):109-16
16258524
Pharmacol Biochem Behav. 2000 Oct;67(2):265-70
11124390
Psychopharmacology (Berl). 2005 Jul;180(2):286-93
15948012
Psychopharmacology (Berl). 2008 Mar;196(4):565-74
18004546
Eur J Neurosci. 2005 Mar;21(6):1749-57
15845103
Psychopharmacology (Berl). 2007 Apr;191(3):507-20
17031711
Pharmacol Biochem Behav. 2001 Jul-Aug;69(3-4):373-82
11509194
Psychopharmacology (Berl). 2002 Mar;160(2):182-91
11875636
Behav Pharmacol. 2001 Dec;12(8):641-5
11856902
Behav Neurosci. 2006 Apr;120(2):488-92
16719712
Behav Pharmacol. 2005 Sep;16(5-6):381-8
16148442
Pharmacol Biochem Behav. 2005 May;81(1):78-88
15894067
Pharmacol Biochem Behav. 1995 Mar;50(3):437-43
7617683
Behav Brain Res. 2008 Nov 21;193(2):298-305
18602425
Psychopharmacology (Berl). 1998 Nov;140(1):81-90
9862406
Psychopharmacology (Berl). 2007 Apr;191(3):579-86
17072593
Psychopharmacology (Berl). 1998 May;137(1):61-6
9631957
Brain Res. 2003 Feb 7;962(1-2):169-79
12543468
Psychopharmacology (Berl). 2002 Apr;160(4):371-80
11919664
Psychopharmacology (Berl). 1991;104(4):515-21
1780422
Eur J Pharmacol. 1996 Jul 4;307(3):331-8
8836622
Science. 1997 Jun 27;276(5321):2048-50
9197269
Pharmacol Biochem Behav. 1991 Nov;40(3):471-8
1666911
Behav Pharmacol. 2003 Dec;14(8):583-8
14665975
Pharmacol Biochem Behav. 2006 Mar;83(3):396-402
16616951
J Exp Anal Behav. 1969 Jul;12(4):605-8
16811382